In drug-resistant SCLC cells, MVP overexpression increased vPARP and TEP1 levels and in resistant ovarian carcinoma A2780TR cell line reduction in MVP expression led to decreased vPARP levels [91,92]. This evidence concerns the gene MVP and ovarian carcinoma.